Article
ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer.
Anticancer research - 1 Sept 2020
Fleschutz Kathrin, Walter Lisa, Leistner Rumo, Heinzerling Lucie
Abstract excerpt
BACKGROUND/AIM: ALK inhibitors like Crizotinib, Ceritinib and Alectinib are targeted therapies used in patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC). Since in this tumor entity radiotherapy is employed sequentially or concomitantly, potential synergistic effects were investigated, which may support the hypothesis of induced radiosensitization by using ALK...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
